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Edited by Gerrit van MeerAbstract Substantial amounts of platelet-activating factor
(PAF 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine), the potent
phospholipid mediator of allergic and inﬂammatory reactions,
are formed upon incubation of acetylated low-density lipopro-
tein, acetylated bovine serum albumin (BSA) and acetylated
apolipoprotein A-I with 1-0-hexadecyl-sn-glycero-3-phosphocho-
line (lyso-PAF). Acetylated BSA produced 0.3 nmol PAF/mg of
protein after a 6 h incubation period with 40 lM lyso-PAF. The
transfer of acetate bound to acetylated proteins to lyso-PAF was
non-enzymatic. Chemical PAF formation by acetylated proteins,
involved in lipid metabolism and transport, could lead to
complication of inﬂammatory and allergic events.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Platelet-activating factor (PAF 1-O-alkyl-2-acetyl-sn-gly-
cero-3-phosphocholine) is a potent lipid mediator of inﬂam-
matory and allergic reactions [1]. PAF synthesis and
degradation by inﬂammatory cells and its circulation in plasma
are tightly enzymatically regulated [2].
Biological protein acetylation is conﬁned to speciﬁc acetyl-
CoA-dependent acetyltransferases [3]. However, protein acet-
ylation by an acetyl-CoA-independent transacetylase [4] and
the non-enzymatic acetylation of proteins [5] have also been
reported. The latter two reactions are utilizing acetylated xe-
nobiotics as the active acetyl donors.
The aim of the present study was to investigate a cell-inde-
pendent PAF formation by acetylated proteins (bovine serum
albumin (BSA) and apolipoprotein A-I (Apo A-I)) or acety-
lated low-density lipoprotein (acetylated LDL) involved in
phospholipid transfer and metabolism in plasma. A non-spe-
ciﬁc non-enzymatic transfer of acetate from acetylated proteins
to the precursor of PAF synthesis, 1-O-hexadecyl-sn-glycero-3-* Corresponding author. Fax: +3026510-47832.
E-mail address: dtsoykat@cc.uoi.gr (D.C. Tsoukatos).
Abbreviations: PAF, platelet-activating factor (1-O-alkyl-2-acyl-sn-
glycero-3-phosphocholine); lyso-PAF, 1-O-hexadecyl-sn-glycero-3-
phosphocholine; C16:0 PAF, 1-O-hexadecyl-PAF; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; BCA, bicinchoninic acid;
Pefabloc, 4-[2-aminoethyl]benzenosulfonyl ﬂuoride; apo A-I, apolipo-
protein A-I; BSA, bovine serum albumin; PBS, phosphate buﬀered
saline
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acetylated proteins in vivo could lead to complication of in-
ﬂammatory and allergic events.2. Materials and methods
2.1. Materials
1-O-Hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16:0 PAF),
1-O-hexadecyl-sn-glycero-3-phosphocholine phosphocreatine, creatine
kinase CaCl2, MgCl2 Æ 6H2O, and FeSO4 Æ 7H20 were from Sigma; 4-[2-
aminoethyl]benzenosulfonyl ﬂuoride (Pefabloc) SC and bicinchoninic
acid (BCA) protein reagent were from Pierce; acetic anhydride was
from Fluka. Solvents were from Lab-Scan. Pre-coated silica gel TLC
plates were purchased from Merck. Sepharose 6B was obtained from
Pharmacia.
LDL and high-density lipoprotein (HDL) were prepared from
freshly isolated human plasma by sequential ultracentrifugation in a
Beckman L7-65 ultracentrifuge as described in [6]. Apo A-I was pu-
riﬁed from HDL according to [7]. The protein content was determined
by the BCA method [8], using BSA as a standard. BSA and delipidated
BSA were purchased from Sigma.2.2. Acetylation of proteins
Proteins were acetylated by acetic anhydride in a saturated sodium
acetate aqueous solution. 1 ml of an aqueous protein solution (approx.
1 mg/ml) and equal volume of a saturated sodium acetate aqueous
solution were mixed and stirred gently at 4 C. 25 ll of acetic anhy-
dride was added in portions of 5 ll for every 15 min and the reaction
mixture was allowed to react for 30 more min. Solutions of the acet-
ylated proteins were dialyzed at 4 C against two changes of 5 l of
phosphate buﬀered saline (PBS) containing 0.05% EDTA at pH 7.4 for
24 h, then were ﬁlter-sterilized and analyzed for their protein content.
The solutions were stored at 4 C. The acetylation of proteins was
determined by measuring the electrophoretic mobility relative to native
proteins on agarose gels.
2.3. PAF formation
Acetylated proteins in PBS (20 mM of phosphate salts) containing
0.05% EDTA at pH 7.4 were incubated in the presence of lyso-PAF
dissolved in PBS containing 0.25% BSA. The ﬁnal concentrations were
0–100 lg of protein/ml, 0–160 lM lyso-PAF and 0.25 mg/ml BSA, in a
reaction mixture of 1.0 ml. Reaction was performed in glass tubes for
0–10 h at 37 C. In some experiments, 50 lg/ml of acetylated BSA was
incubated with 40 lM of lyso-PAF for 6 h in PBS containing 0.05%
EDTA at pH 3.0 (adjusted with 12 N HCl) and at pH 9.0 (adjusted
with 10 N NaOH). In other experiments, the incubation temperatures
were at 4 and 50 C. Other experiments yet were performed in the
presence of 5 mM Ca2þ, 5 mM Mg2þ or 0.15 mM Fe2þ. In the ex-
periments with metal ions EDTA was omitted from the incubation
buﬀer and in the experiment with Ca2þ PBS was replaced by Tris
buﬀered saline. The reaction was stopped by extracting the lipids ac-
cording to Bligh and Dyer [9]. Total lipids were then subjected to TLC
on silica-gel G plates by using chloroform/methanol/water (65:35:6, v/
v) as a solvent system. Lipids were identiﬁed after a brief exposure to
iodine. The band corresponding to the Rf of authentic PAF was
scraped oﬀ the plate and PAF was extracted from silica gel by the
method of Bligh and Dyer. The TLC puriﬁcation was necessary inblished by Elsevier B.V. All rights reserved.
Fig. 1. PAF-like aggregating activity formation in acetylated BSA.
Washed rabbit platelets were stimulated with (a) 40 lM lyso-PAF, (b)
50 lg/ml acetylated BSA, (c) sample obtained as described under
Section 2 upon 6 h incubation of 50 lg/ml BSA with 40 lM lyso-PAF,
(d) sample obtained as described under Section 2 upon 6 h incubation
of 50 lg/ml acetylated BSA with 40 lM lyso-PAF, and (e) standard
C16:0 PAF.
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in acetylated LDL or in acetylated BSA. The TLC-puriﬁed lipids were
dissolved in 60% (v/v) ethanol and assayed for platelet-aggregating
activity against aspirin-treated washed rabbit platelets as described
previously [10]. Platelet aggregation assays were performed using a
Chronolog aggregometer in the presence of the ADP scavenger com-
plex phosphocreatine (1 mM)/creatine kinase (10 U/ml). The aggre-
gating activity of PAF was expressed as nM of C16:0 PAF equivalents
using a calibration curve obtained with standard solutions of C16:0
PAF. In the experiments with acetylated LDL, the lipoprotein was
preincubated with 1 mM Pefabloc for 30 min at 37 C before the ad-
dition of lyso-PAF.
In some experiments, acetylated LDL and acetylated BSA were
puriﬁed by size exclusion chromatography before the assay. The so-
lutions of proteins were applied to a Sepharose 6B column using an
aqueous solution containing 10 mM Tris–base (Tris–(hydroxylm-
ethyl)aminomethane), 1 mM EDTA, 1 mM NaCl and 0.02% NaN3 at
pH 7.4 as a solvent. The eluted protein solutions were concentrated
using an Amicon concentrating apparatus and dialyzed as described
above.
2.4. Puriﬁcation of PAF by RP-HPLC and characterization by GC–MS
In order to determine the molecular species responsible for PAF-like
bioactivity, in some experiments the TLC puriﬁed lipids were further
puriﬁed by RP-HPLC and analyzed by GC–MS. Samples containing a
known quantity of PAF-like bioactivity were suspended in 25 ll of
HPLC mobile phase (ammonium acetate (10 mM)/acetonitrile/meth-
anol (120:140:40, v/v/v)) before separation of the molecular species of
PAF on a reversed-phase Spherisorb C6 column (Touzart et Mati-
gnon, Vitry/Seine, France). The retention time of PAF was determined
using [3H] labeled C16:0 standard as described in [11]. Fractions were
collected, extracted with chloroform, dried and assayed for PAF
content by the washed rabbit platelet bioassay. The yield of platelet-
aggregating activity of PAF upon separation by reversed-phase HPLC
varied between 70% and 80%.
The biologically active material, which was recovered from reversed
phase-HPLC with the retention time of C16:0 PAF, was further ana-
lyzed by GC/MS as described in [12]. In brief, the samples from
reversed phase-HPLC were added to tubes which contained 20 ng of
the stable, isotopically labeled variant of PAF, 1-O-hexadecyl-2(D3)-
acetyl-glycero-3-phosphocholine (D3-PAF). The samples were re-
dissolved in ethanol and applied to silica solid phase extractor tubes
(Varian, Harbor City, CA, USA). The tubes were washed with 4 ml
ethanol and then eluted with 4 ml of methanol:water (4:1). The samples
were then dried and subjected to phospholipase C cleavage. The di-
glycerides thus produced were extracted into methylene chloride, dried
and then derivatized with pentaﬂuorobenzoyl chloride. The penta-
ﬂuorobenzoyl derivatives were subsequently analyzed by negative ion
chemical ionization GC/MS with a Finnigan Mat (San Jose, CA)
SSQ70 mass spectrometer, as described in [12].Fig. 2. (A) Reversed phase HPLC puriﬁcation of PAF-like molecules formed
40 lM lyso-PAF. Bioactive phospholipids with the Rf of PAF on TLC were s
tested for their ability to aggregate washed rabbit platelets and the bioactivity
of synthetic C16:0 PAF. (B) GC/MS analysis of the RP-HPLC puriﬁed PAF-l
HPLC was analyzed by GC/MS as described under Section 2. In the ﬁgure, rec
speciﬁc ions m/z 552 and m/z 555 is shown. The ion m/z 552 corresponds to C1
of the internal standard D3-PAF derivative, respectively. The ratio of the ion
unlabeled PAF diglyceride was used to calculate the quantity of C16:0 PAF3. Results
A lipoprotein (LDL), a HDL apolipoprotein (apo A-I), a
plasma lipid carrier protein (BSA), plus its delipidated form
were submitted to chemical acetylation as described in Section
2. The higher electrophoretic mobility of acetylated proteins
relative to controls on agarose gel electrophoresis suggests
acetylation at positive charged NH2 containing residues, via
amide bond formation. As shown in Fig. 1, upon incubation
with lyso-PAF, acetylated BSA was able to produce a PAF-
like bioactivity. Similar results were obtained with the other
proteins or the lipoprotein of the study. RP-HPLC puriﬁcation
followed by GC–MS analysis revealed that the bioactive
product of the reaction was C16:0 PAF (Fig. 2). The ion peak
at m/z 552 was the [M+H]þ of the pentaﬂuorobenzoyl deriv-
ative of C16:0 PAF, after hydrolysis with phospholipase C. Its
retention time on Gas Chromatography was identical with
those of the internal standard D3-PAF derivative (m/z 555).
Results with acetylated LDL are presented in Fig. 2. Similarin Pefabloc treated acetylated LDL incubated for 6 h in the presence of
eparated by C6 RP-HPLC as described under Section 2. Fractions were
was expressed as ng of C16:0 PAF equivalents. Arrow indicates the RT
ike molecule. The PAF-like molecule with the RT of C16:0 PAF on RP-
onstructed ion chromatogram obtained during GC/MS analysis for the
6:0 PAF derivative, present in the sample, and the ion m/z 555 to 20 ng
abundance area of the elution of the D3-PAF diglyceride to that of the
in the sample.
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Fig. 3. (A) PAF formation by acetylated proteins. Acetylated proteins
(0–100 lg/ml) were incubated with lyso-PAF (40 lM) at 37 C for 6 h.
Acetylated LDL was preincubated with 1 mM Pefabloc for 30 min at
37 C before the addition of lyso-PAF. Values are means S.D. of
three experiments. (B) PAF formation by acetylated proteins as a
function of time. Acetylated proteins and Pefabloc treated acetylated
LDL (50 lg/ml) were incubated with lyso-PAF (40 lM) at 37 C for
the indicated periods. Values are means S.D. of three experiments.
(C) PAF formation by acetylated proteins as a function of lyso-PAF
concentration. Acetylated proteins and Pefabloc treated acetylated
LDL were incubated with lyso-PAF at 37 C for 6 h. Values are
means range of two experiments.
Table 1
Rate of PAF formation by acetylated BSA under diﬀerent incubation
conditions
Incubation conditions % Of control rate
Controla 100 32b
4 C 4 0
50 C 130 28
pH 3.0 4 1
pH 9.0 281 19
Ca2þ 5 mM 82 15
Mg2þ 5 mM 113 23
Fe2þ 0.15 mM 106 24
Values represent the mean range of two experiments.
a Control incubation conditions were: 50 lg/ml acetylated BSA protein
incubated with 40 lM lyso-PAF at 37 C and pH 7.4 for 6 h.
b The control rate in these experiments was 6.3 nM PAF per 6 h.
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of C16:0 PAF by the washed rabbit platelet aggregation assay,
and by the RP-HPLC GC–MS analysis described in the legend
of Fig. 2, gave similar results, thus throughout the study PAF
quantiﬁcation was performed by the bioassay. The dependence
of PAF formation from the concentration of acetylated pro-
teins is shown in Fig. 3A. PAF formation was linear up to 6 h
of incubation (Fig. 3B) and increased up to 120 lM of lyso-
PAF (Fig. 3C). The amount of PAF formed was the highest in
acetylated BSA reaching 0.3 nmol/mg protein upon 6 h incu-bation of 50 lg/ml protein with 40 lM lyso-PAF. The amount
of PAF was similar in acetylated delipidated BSA, but lower in
acetylated apo A-I. Acetylated LDL produced the lowest
amount of PAF and PAF formation was observed only upon
inhibition of the LDL attached PAF acetylhydrolase by 1 mM
Pefabloc treatment of LDL for 30 min at 37 C [13]. PAF
formation was not observed in acetylated LDL in the absence
of Pefabloc treatment.
In order to test the possibility that acetate bound to acety-
lated protein and non-free acetate of the incubation mixture
are transferred to lyso-PAF, we submitted acetylated LDL and
acetylated BSA to Size Exclusion Chromatography prior to
the incubation with lyso-PAF. The amount of PAF bioactivity
formed was similar before and after the chromatographic pu-
riﬁcation, suggesting that acetate bound to protein residues
rather than free acetate was transferred to lyso-PAF.
Characterization of the reaction with acetylated BSA as the
donor protein is shown in Table 1. The rate of the reaction was
increased at pH 9 and was very low at pH 3. Moreover, the
reaction rate was increased with rising temperature from 4 to
50 C. The reaction was independent from the presence of
metal ions at normal plasma concentrations.4. Discussion
Our results showed that substantial amounts of PAF are
formed by acetylated proteins incubated with lyso-PAF. A
transfer of acetate, bound to protein, to lyso-PAF seems to be
responsible for the above formation. We recently reported an
enzymatic transfer of acetate from acetylated phospholipids to
lyso-phospholipids, in LDL, catalyzed by the LDL attached
PAF acetylhydrolase [14]. The above enzymatic transfer was
sensitive to serine esterase inhibitors and was inhibited 100%
by 1 mM Pefabloc. The insensitivities to Pefabloc formation of
PAF in acetylated LDL and the non-speciﬁc formation of PAF
by the other acetylated proteins of the study, which are not
possessing enzymatic transacetylase activity, suggest that the
transfer of acetate is chemical rather than enzymatic. The
characteristics of the reaction and especially its pH dependence
further support the above assumption. The nucleophilic attack
of the sn-2 OH group of lyso-PAF on the amide bond, which
may lead to acetate transfer and subsequently to PAF for-
mation, is expected to be enhanced at high pH values.
Enzymatic and non-enzymatic biological protein acetylation
have been reported. The acetyl-CoA-dependent acetylation of
14 P.G. Thanou, D.C. Tsoukatos / FEBS Letters 573 (2004) 11–14histones, catalyzed by histone acetyl transferase, stands
prominent [3]. Moreover, various types of proteins are known
to undergo non-enzymatic acetylation when treated with as-
pirin [15,16]. Recently, an enzyme in rat liver microsomes that
catalyzes the transfer of acetyl group from acetoxy xenobiotics
to speciﬁc proteins was also described [4]. Enzyme acetylation
is leading to modulation of their catalytic activities. The most
familiar example is the observation that aspirin (acetylsalicy-
late) acetylates cyclooxygenase resulting in the inhibition of
prostaglandin synthesis [5].
The protein, the lipoprotein and the apolipoprotein selected
in the present study are involved in lipid transfer and metab-
olism in plasma. A biological function of albumin is to
transport lipids by binding and solubilizing plasma fatty acids
and lyso-phospholipids. A signiﬁcant fraction of cellular PAF
is secreted and transported by the circulation in association
with albumin [17]. Apo A-I, a HDL apolipoprotein, is im-
portant in initiating reverse cholesterol transport and is the
apoprotein activator of lecithin-cholesterol acyltransferase
[18–20]. LDL modiﬁcation by oxidation or chemical and en-
zymatic treatment is thought to be an initiating and sustaining
event in atherogenesis [21,22]. The chemically modiﬁed LDL
by acetylation is the ﬁrst modiﬁed LDL discovered, which was
taken up by the scavenger receptor of the monocyte derived
macrophages leading to foam cell formation, the early step of
atherogenesis [23]. Thus, acetylated LDL is used in experi-
ments as a model of modiﬁed LDL [24]. PAF formation in
acetylated LDL may be at least partially responsible for the
inﬂammatory atherogenic eﬀect of these particles.
A chemical acetylation of lyso-PAF by aspirin has been re-
ported [25]. Moreover, aspirin is able to acetylate BSA [16,26].
PAF formation observed in the present study by acetylated
BSA was several times higher than the one reported resulting
from mixing lyso-PAF with aspirin in a buﬀer [25]. Thus me-
diation of a protein may enhance chemical PAF formation by
a widely used acetylated xenobiotic.
It is not clear whether non-enzymatic formation of PAF
from lyso-PAF and acetylated proteins takes place in vivo and
further detailed studies are indispensable to clarify if non-en-
zymatic formation of PAF is actually of practical importance.
PAF synthesis and degradation in cells and in blood are tightly
enzymatically regulated. The results of the present study sug-
gest that chemical formation of PAF by proteins acetylated by
physiological metabolites or xenobiotics may break down the
above regulatory system, leading to complications of inﬂam-
matory and allergic events.References
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